Ozagrel
Chemical compound
- none
- In general: ℞ (Prescription only)
- (2E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]acrylic acid
- 82571-53-7
Y
- 5282440
- 4445594
N
- L256JB984D
- D08327
Y
- ChEMBL11662
N
- DTXSID6048547
![Edit this at Wikidata](http://upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png)
- Interactive image
- C1=CC(=CC=C1CN2C=CN=C2)/C=C/C(=O)O
InChI
- InChI=1S/C13H12N2O2/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15/h1-8,10H,9H2,(H,16,17)/b6-5+
N
- Key:SHZKQBHERIJWAO-AATRIKPKSA-N
N
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Ozagrel (INN) is an antiplatelet agent working as a thromboxane A2 synthesis inhibitor.[1]
References
- ^ Loo MH, Egan D, Vaughan ED, Marion D, Felsen D, Weisman S (March 1987). "The effect of the thromboxane A2 synthesis inhibitor OKY-046 on renal function in rabbits following release of unilateral ureteral obstruction". J. Urol. 137 (3): 571–6. doi:10.1016/s0022-5347(17)44108-5. PMID 3820396.
- v
- t
- e
Prostanoid signaling modulators
(ligands)
DP (D2)Tooltip Prostaglandin D2 receptor |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
EP (E2)Tooltip Prostaglandin E2 receptor |
| ||||||||||
FP (F2α)Tooltip Prostaglandin F receptor |
| ||||||||||
IP (I2)Tooltip Prostacyclin receptor |
| ||||||||||
TP (TXA2)Tooltip Thromboxane receptor |
| ||||||||||
Unsorted |
|
(inhibitors)
- Precursors: Linoleic acid
- γ-Linolenic acid (gamolenic acid)
- Dihomo-γ-linolenic acid
- Diacylglycerol
- Arachidonic acid
- Prostaglandin G2
- Prostaglandin H2
- See also
- Receptor/signaling modulators
- Leukotriene signaling modulators
![]() | This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e